Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124,314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif® in healthy Chinese subjects.
Liu G, Xue J, Wang Y, Liu Z, Li X, Qu D, Su Z, Xu K, Qu X, Qu Z, Sun L, Cao M, Wang Y, Chen X, Yu J, Liu L, Deng Q, Zhao Y, Zhang L, Yang H. Liu G, et al. Among authors: zhang l. J Cancer Res Clin Oncol. 2023 Jun;149(6):2585-2593. doi: 10.1007/s00432-022-04148-1. Epub 2022 Jun 30. J Cancer Res Clin Oncol. 2023. PMID: 35771264 Clinical Trial.
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects.
Liu Z, Gao Z, Yang W, Zhang L, Xiao N, Qu D, Su Z, Xu K, Liu G, Wang Y, Ren Q, Yu S, Cheng Y, Zhou Y, Deng Q, Zhao Y, Wang Z, Yang H. Liu Z, et al. Among authors: zhang l. Expert Opin Drug Metab Toxicol. 2022 Jul-Aug;18(7-8):519-527. doi: 10.1080/17425255.2022.2113382. Epub 2022 Aug 18. Expert Opin Drug Metab Toxicol. 2022. PMID: 35961948 Clinical Trial.
Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjects.
Liu Z, Xue J, Deng Q, Wang Y, Zhang L, Liu L, Xiao N, Chang T, Cui Y, Cheng Y, Liu G, Wang W, Zhou Y, Yang W, Qu X, Chen J, Zhao Y, Wang Z, Yang H. Liu Z, et al. Among authors: zhang l. Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr 21. doi: 10.1007/s00210-024-03055-1. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38643450
Effects of Lianhuaqingwen Capsules in adults with mild-to-moderate coronavirus disease 2019: an international, multicenter, double-blind, randomized controlled trial.
Zheng JP, Ling Y, Jiang LS, Mootsikapun P, Lu HZ, Chayakulkeeree M, Zhang LX, Arttawejkul P, Hu FY, Truong TNL, Perez RA, Gu X, Sun HM, Jiang JJ, Liu RJ, Ding Z, Zhan YQ, Yang ZF, Guan WJ, Zhong NS. Zheng JP, et al. Virol J. 2023 Nov 28;20(1):277. doi: 10.1186/s12985-023-02144-6. Virol J. 2023. PMID: 38017515 Free PMC article. Clinical Trial.
Recent Developments in Single-Entity Electrochemistry.
Zhang L, Wahab OJ, Jallow AA, O'Dell ZJ, Pungsrisai T, Sridhar S, Vernon KL, Willets KA, Baker LA. Zhang L, et al. Anal Chem. 2024 May 10. doi: 10.1021/acs.analchem.4c01406. Online ahead of print. Anal Chem. 2024. PMID: 38727715 Review. No abstract available.
HIV rebound in HIV controllers is associated with a specific fecal microbiome profile.
Cai Y, Podlaha O, Deeks SG, Brinson C, Ramgopal MN, DeJesus E, Mills A, Shalit P, Abdel-Mohsen M, Zhang L, de Vries CR, Vendrame E, SenGupta D, Wallin JJ. Cai Y, et al. Among authors: zhang l. Eur J Immunol. 2024 May 10:e2350809. doi: 10.1002/eji.202350809. Online ahead of print. Eur J Immunol. 2024. PMID: 38727191
124,314 results
You have reached the last available page of results. Please see the User Guide for more information.